Another inhibitor of GRP78, ruthenium(II) triazine complex [Ru(bdpta)(tpy)]2+, reduced the GRP78 protein level in CD133+ CSCs derived from human colon cancer HCT-116 cells; the inhibitor-induced GRP78 downregulation was correlated in a dose-dependent manner with the in vivo-achieved antitumor effects toward tumor xenografts [239]. This evidence concerns the gene HSPA5 and malignant colon neoplasm.